Active Filter(s):
Details:
XOMA acquired an economic interest in DSUVIA® (sufentanil sublingual tablet), an opioid agonist, indicated for use in adults, for the management of acute pain, from Talphera.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: XOMA
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 18, 2024